𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation

✍ Scribed by Ioannis U. Isaias; Riccardo Benti; Stefano Goldwurm; Michela Zini; Roberto Cilia; Paolo Gerundini; Alessio Di Fonzo; Vincenzo Bonifati; Gianni Pezzoli; Angelo Antonini

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
58 KB
Volume
21
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

We measured striatal dopamine transporter binding using [(123)I]ioflupane and SPECT in patients with Parkinson's disease associated with the LRRK2 (PARK8) Gly2019Ser gene mutation (LRRK2-PD) and in gene-negative patients with idiopathic Parkinson's disease (IPD) of comparable disease duration and severity. The LRRK2-PD group consisted of a total of 10 patients (3 sporadic) with mean age 62 +/- 14 years, disease duration 9 +/- 3 years, and UPDRS III motor score 21.60 +/- 6.65. The control IPD group consisted of 15 patients with mean age 59 +/- 9 years, disease duration 9 +/- 5 years, and UPDRS III motor score 23.80 +/- 8.69. [(123)I]ioflupane-specific uptake ratios were calculated for caudate nucleus and putamen using the occipital cortex as reference region. We found no differences between the LRRK2-PD group and IPD in all items studied. In particular, putamen and caudate uptake values as well as side asymmetry indexes and putamen/caudate ratios all revealed comparable between-group values. We conclude that in these patients carrying the LRRK2 Gly2019Ser mutation, the neurodegenerative process results in a pattern of nigrostriatal dopaminergic dysfunction similar to that observed in IPD.

📜 SIMILAR VOLUMES

LRRK2 G2019S mutations are associated wi
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease
✍ Rachel Saunders-Pullman; Matthew J. Barrett; Kaili M. Stanley; Marta San Luciano 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract Leucine rich repeat kinase (__LRRK2__) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may nonspe

Neuropathology of Parkinson's disease as
Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation
✍ Maria Teresa Giordana; Carla D'Agostino; Giovanni Albani; Alessandro Mauro; Ales 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 144 KB

## Abstract __Leucine‐Rich Repeat Kinase 2__ (__LRRK2__) gene mutations are the most common known cause of Parkinson's disease (PD), but neuropathological studies are available on very few patients with __LRRK2__ mutation. The reported findings range from Lewy body–positive pathology to different p

The G2019S LRRK2 mutation in Brazilian p
The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: Phenotype in monozygotic twins
✍ Renato P. Munhoz; Yosuke Wakutani; Connie Marras; Helio A. Teive; Salmo Raskin; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract Mutations in the Leucine‐Rich Repeat Kinase 2 gene (__LRRK2__) are mainly responsible for idiopathic Parkinson's disease (PD) with either a dominant pattern of transmission or a sporadic occurrence due to the reduced penetrance. A majority of __LRRK2__ kindreds demonstrate an extremely

Neuropathology of Parkinson's disease wi
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2
✍ José-Félix Martí-Massó; Javier Ruiz-Martínez; Maria J. Bolaño; Irune Ruiz; Ana G 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 348 KB

## Abstract We report the neuropathological findings in a patient with Parkinson's disease (PD) associated with Basque R1441G‐__LRRK2__/dardarin mutation. The patient was a man with disease onset at 68 years of age, with unilateral rest tremor; the Parkinsonism was well controlled with medication f

Striatal dopamine transporter imaging co
Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease
✍ Irena Rektorova; Hana Srovnalova; Radka Kubikova; Jiri Prasek 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 1 views

## Abstract We studied whether the ^123^I‐FP‐CIT uptake in the striatum correlates with depressive symptoms and cognitive performance in patients with Parkinson's disease (PD). Twenty patients with PD without major depression and/or dementia (mean age 61.7 ± 12.7 years) underwent the ^123^I‐FP‐CIT

Association of a polymorphism in the dop
Association of a polymorphism in the dopamine-transporter gene with parkinson's disease
✍ Dr. David G. le Couteur; Peter W. Leighton; Sally J. McCann; Susan M. Pond 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 341 KB 👁 1 views

## Abstract The presynaptic dopamine transporter in nigral dopaminergic neurons confers susceptibility to the cytotoxic effects of the neurotoxic metabolite of 1‐methy1‐4‐phenyl‐1,2,3,6‐tetrahydropyridine. Polymorphisms in the dopamine transporter might influence the susceptibility to such toxins.